Placebo THC

Phase 2

TTiffany J. Braley, MD, MS

Placebo THC is one of 34 therapeutic programs targeting Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple SclerosisRecruiting

Multiple SclerosisPhase 2

Recruiting

Competition

Competitive Landscape

138 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 2

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 3

Clemastine Fumarate

Novartis

Phase 3

2 4

Activated Charcoal

Sanofi

Phase 3

1 5

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

Phase 3

1 6

MRI Contrast-Enhancing Agents

Sanofi

Phase 3

3 7

Frexalimab

Sanofi

Phase 3

2 8

PBR06

UUniversity Hospital, Bordeaux

Phase 3

4 9

Flomax

Sanofi

Preclinical

1 10

Myfortic

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Multiple Sclerosis

NCT05269628

Clinical

Trials by Indication[1]

Multiple Sclerosis1 trial

Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype

Recruiting·TTiffany J. Braley, MD, MS·Phase 2·NCT05269628·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo THC. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo THC. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tiffany J. Braley, MD, MS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTiffany J. Braley, MD, MS

Placebo THC

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News